400-920-2911 sales@csnpharm.cn
CDK
货号 | 产品名 | CAS号 | 信息 |
---|---|---|---|
CSN17914 | WHI-P180 HCl | 153437-55-9 | WHI-P180 HCl is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 μM, respectively. |
CSN20480 | THZ531 | 1702809-17-3 | THZ531 is a covalent CDK12 and CDK13 inhibitor with IC50s of 158 nM and 69 nM. |
CSN17944 | THZ2 | 1604810-84-5 | THZ2 is a potent and selective CDK7 inhibitor with in vitro IC50 of 13.9 nM. |
CSN17959 | THZ1-R | 1621523-07-6 | THZ1-R is a non-cysteine reactive analog, which displays diminished activity for CDK7and reduces anti proliferative potency. |
CSN18930 | THZ1 Hydrochloride | 2070018-35-6 | THZ1 HCl is a selective and potent covalent CDK7 inhibitor with IC50 of 3.2 nM. |
CSN19264 | N-(3-((5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide dihydrochloride | 2095433-94-4 | THZ1 2HCl is a Cdk7 inhibitor (IC50s = 3.2-15.6 nM in vitro) that selectively targets a remote cysteine residue located outside of the classic kinase domain. THZ1 2HCl also targets Cdk12 kinase activity although at a higher concentration (IC50 = 250 nM). |
CSN22287 | THAL-SNS-032 | 2139287-33-3 | THAL-SNS-032 is a selective PROTAC, consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN), targeting on CDK9. |
CSN20233 | TG693 | 885272-55-9 | TG693, an orally available inhibitor of CLK1, promotes the skipping of the endogenous mutated exon 31 in Duchenne muscular dystrophy (DMD) patient-derived cells and increased the production of the functional exon 31-skipped dystrophin protein. |
CSN23736 | (8E)-6-Methyl-21,22-dihydro-12-oxa-3,6-diaza-2(6,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-ene | 1204918-72-8 | TG02 (Double bond E) is the Double key form of TG02. TG02 is a small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively. |
CSN22563 | (E/Z)-TG003 | 300801-52-9 | TG003 is a potent, reversible ATP-competitive inhibitor of Cdc-2 like kinase (Clk) with IC50s of 20 nM and 15 nM for Clk1/Sty and Clk4. |
CSN20451 | 3-((1H-Imidazol-5-yl)methylene)-5-methoxyindolin-2-one | 666837-93-0 | SU9516 (mixture) is a 3-substituted indolinone compound and a competitive inhibitor of CDC2 CDK2 and CDK4 that displaying anti-proliferative and proapoptotic properties in tumor cells. It is the mixture form of SU9516. |
CSN23674 | SEL120-34A HCl | 1609452-30-3 | SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity. |
CSN18607 | (E/Z)-Zotiraciclib | 937270-47-8 | SB-1317 is a small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively. |
CSN19761 | Roniciclib | 1223498-69-8 | Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. |
CSN18432 | RGB-286638 | 784210-87-3 | RGB-286638 is a CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively and less potent against cyclin H-CDK7 and cyclin D3-CDK6. |
CSN18433 | RGB-286638 free base | 784210-88-4 | RGB-286638 free base is a CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively and less potent against cyclin H-CDK7 and cyclin D3-CDK6. |
CSN22310 | CDK9 PROTAC compound 3 | 2118356-96-8 | PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide. |
CSN18614 | 2-(Pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one hydrochloride | 942425-68-5 | PHA-767491 HCl is a potent and ATP-competitive cyclin-dependent kinase (cdk) inhibitor with IC50 values of 10/34 nM for Cdc7/Cdk9. |
CSN18553 | NVP-LCQ195 | 902156-99-4 | NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM. |
CSN18926 | NU6300 | 2070015-09-5 | NU6300 is the first covalent ATP-competitive CDK2 inhibitor. |
CSN19184 | NU6027 | 220036-08-8 | NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors. |
CSN18851 | NSC23005 Sodium | 1796596-46-7 | NSC 23005 Sodium is an effective p18 inhibitor with ED50 of 5.21 nM in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models. |
CSN19672 | MSC2530818 | 1883423-59-3 | MSC2530818 is a Potent, Selective, and Orally Bioavailable CDK8 inhibitor with CDK8 IC50 = 2.6 nM. |
CSN18809 | LY3177833 | 1627696-51-8 | LY3177833 is an CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. |
CSN17957 | LY2857785 | 1619903-54-6 | LY2857785 is a potent and selective CDK9 inhibitor and significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines. |
CSN20517 | LDC4297 | 1453834-21-3 | LDC4297 is a potent CDK7 selective inhibitor with IC50 of 0.13 ± 0.06 nM. |
CSN18916 | AUZ 454 | 853299-07-7 | K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2 (WT), CDK2 (C118L), CDK2 (A144C), and CDK2 (C118L/A144C), respectlvely. |
CSN22284 | JH-XI-10-02 | 2209085-22-1 | JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide. |
CSN19698 | Lerociclib | 1628256-23-4 | G1T38 is a potent, selective, and orally bioavailable CDK4/6 inhibitor with unique pharmacokinetic and pharmacodynamic properties, which result in high efficacy against CDK4/6 dependent tumors while minimizing the undesirable on-target bone marrow activity. |
CSN21361 | FN-1501 | 1429515-59-2 | FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively; has anticancer activity. |
CSN18431 | Dinaciclib | 779353-01-4 | Dinaciclib is a potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively. |
CSN21181 | Samuraciclib HCl | 1805789-54-1 | CT7001 HCl is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
CSN22379 | CDK12-IN-3 | 2220184-50-7 | CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. |
CSN20276 | CLK-IN-T3 | 2109805-56-1 | Clk inhibitor T3 is a highly selective, stable CLK inhibitor with high specificity to CLK1-3 protein isoforms. |
CSN20232 | Clk Inhibitor C21b | 2101206-26-0 | Clk inhibitor C21b, a potent inhibitor of Clk1 and -4 (IC50 = 7 and 2.3 nM, respectively), exhibits an unprecedented selectivity over Dyrk1A. It triggered the depletion of EGFR, HDAC1, and p70S6 kinase from the cancer cells, with potencies in line with the measured GI50 values. |
CSN17828 | Asnuciclib | 1421693-22-2 | CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM and shows selective toxicity to CLL cells (LD50=80 nM) versus normal B cell and normal CD34+ cell (LD50> 20 μM). |
CSN22366 | CDK8/19-IN-1 | 1818427-07-4 | CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively. |
CSN22368 | CDK8-IN-4 | 1613638-82-6 | CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM. |
CSN22367 | CDK8-IN-3 | 1884500-15-5 | CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7. |
CSN19756 | Cdc7 inhibitor 7c | 1330781-04-8 | CDC7 inhibitor C10C is a high selective CDC7 inhibitor. |
CSN18782 | CCT-251921 | 1607837-31-9 | CCT251921 exhibits excellent pharmacokinetic profile and high potency in vitro and in vivo effects c-Myc downregulation and tumor growth inhibition in xenograft studies. |
CSN23778 | CC-671 | 1618658-88-0 | CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively. |
CSN20540 | BRD6989 | 642008-81-9 | BRD6989 selectively upregulates IL-10 through inhibiting CDK8 activity. |
CSN24735 | AZD4573 | 2057509-72-3 | AZD4573 is a potent and selective CDK9 inhibitor with with nanomolar. |
CSN21194 | Atuveciclib Racemate | 1414943-88-6 | Atuveciclib Racemate is the racemate form of Atuveciclib. |
CSN17844 | AT7519 TFA | 1431697-85-6 | AT 7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM and less potent to CDK3 and little active to CDK7. |
CSN21360 | AMG 925 HCl | 1401034-19-2 | AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively. |
CSN22673 | Alsterpaullone | 237430-03-4 | Alsterpaullone is a potent CDK1 and 2 inhibitor with IC50s of 0.035 and 0.08 μM, respectively. It also inhibits GSK-3β and Lck with IC50s of 0.11 and 0.47 μM, respectively. |
CSN22626 | (R)-CR8 | 294646-77-8 | (R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 - 0.07 and 0.09 - 0.8 μM for cdk2 and cdk1,respectively. |
CSN21345 | Enitociclib | 1610358-56-9 | (+)-BAY-1251152 is a CDK9 inhibitor, Phase 1 of Neoplasms. |